Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study
Fiche du document
2023
- handle: 10670/1.il8leh
Cairn
Mots-clés
psoriasis body surface area (BSA) Dermatology Life Quality Index (DLQI) Investigator Global Assessment (IGA) Minimal Disease Activity (MDA) Psoriasis Area and Severity Index (PASI) secukinumabSujets proches
illnessCiter ce document
Anna Campanati et al., « Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study », European Journal of Dermatology, ID : 10670/1.il8leh
Métriques
Partage / Export
Résumé
Background: Achieving minimal disease activity (MDA) represents an ambitious and sustainable therapeutic goal in psoriasis. Clear criteria for defining MDA in psoriasis are lacking. Objectives: The primary outcome was to evaluate the effect of 300 mg secukinumab in achieving MDA in patients with psoriasis and identify the most useful criteria to define MDA in such patients. The secondary outcome was to identify clinical factors influencing MDA. Materials & Methods: In this post hoc analysis of the SUPREME study, in which 433 patients were enrolled, MDA was assessed using established criteria: ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) and Dermatology Life Quality Index 0/1 (MDA-1), PASI score ≤1 or body surface area (BSA)